Abstract:Background: Cancer is the most prevalent disease seen nowadays. Thymidine phosphorylase (TP) is an angiogenic enzyme that is overexpressed in many solid tumors. Over the years, Thymidine phosphorylase has emerged as a novel target for anticancer drug development as an inhibitor. Objective: To design novel oxadiazole-isatin pharmacophore containing molecules and to explore their structural requirements related to the anticancer activity. Methods: Pharmacophore optimisation was carried out for oxadiazole-isatin hybrid molecules using molecular modeling studies (2D and 3D QSAR). Further, the new chemical entities were designed using combilib tool of V life software. To have a better understanding of the binding interactions, the newly designed molecules were docked. To achieve a drug-like pharmacokinetic profile, molecules were also tested for ADME prediction. Results: For Two-Dimensional Quantitative Structure-Activity Relationship (2D-QSAR) model was generated using the multiple regression method with r2 = 0.84 and q2 = 0.76. Three-Dimensional Quantitative Structure-Activity Relationship (3D-QSAR) model was obtained by simulated annealing k nearest near (SA kNN) method with q2 = 0.8099. Molecular docking studies showed promising results. The compound with the best dock score and the best fit to the active site pocket of the thymidylate phosphorylase enzyme was found to be compound 5. The compounds have notable absorption, distribution, metabolism, and excretion (ADME) properties that can be predicted to assure a drug-like pharmacokinetic profile. Conclusion: One of the most successful and fast-increasing methodologies is molecular modeling. It not only aids in the prediction of specific target compounds but also aids in the cost reduction of valuable substances. The successful use of molecular modeling was done in this study, with caution taken to avoid any chance co-relation. Optimised pharmacophore was obtained and new chemical entities were designed. Docking studies revealed that Molecule 5 have shown better H-bond interaction with Lys 221 and Thr 151 with bond distances 2.0  and 1.8  which is the most active molecule. ADME tests discovered that the majority of the newly designed compounds were within a reasonable range as required in a drug like pharmacokinetic profile. Molecules 2, 4, 5, 6 can be considered as a lead for future synthesis and biological screening.

Discovery of Thiadiazoles as Human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors by Combined Structure‐Based Modelling Methods

[Design, Synthesis and Structure-Activity Relationship Studies of Human Dihydroorotate Dehydrogenase Inhibitors].

Discovery a Series of Novel Inhibitors of Human Dihydroorotate Dehydrogenase: Biological Activity Evaluation and Molecular Docking.

Structural Optimization and Structure–Activity Relationship of 4-Thiazolidinone Derivatives As Novel Inhibitors of Human Dihydroorotate Dehydrogenase

Discovery of Nanomolar Inhibitors for Human Dihydroorotate Dehydrogenase Using Structure-Based Drug Discovery Methods

Development of a Human Dihydroorotate Dehydrogenase (hdhodh) Pharma-Similarity Index Approach with Scaffold-Hopping Strategy for the Design of Novel Potential Inhibitors.

Design, Synthesis, X-ray Crystallographic Analysis, and Biological Evaluation of Thiazole Derivatives As Potent and Selective Inhibitors of Human Dihydroorotate Dehydrogenase.

Synthesis, Molecular Docking and Antitumor Activity of New Dithiazoles

Structure-based design of potent human dihydroorotate dehydrogenase inhibitors as anticancer agents

Synthesis, structure-activity relationship and binding mode analysis of 4-thiazolidinone derivatives as novel inhibitors of human dihydroorotate dehydrogenase.

A Rational Approach to Anticancer Drug Design: 2D and 3D- QSAR, Molecular Docking and Prediction of ADME Properties Using Silico Studies of Thymidine Phosphorylase Inhibitors

Rational Design of Benzylidenehydrazinyl-Substituted Thiazole Derivatives As Potent Inhibitors of Human Dihydroorotate Dehydrogenase with in Vivo Anti-arthritic Activity.

Design and Synthesis of Thiazole Scaffold-Based Small Molecules as Anticancer Agents Targeting the Human Lactate Dehydrogenase A Enzyme

Pharmacophore-based discovery of new human dihydroorotate dehydrogenase inhibitor.

Design, Synthesis and Inhibitory Activity Against Human Dihydroorotate Dehydrogenase (hdhodh) of 1,3-Benzoazole Derivatives Bearing Amide Units.

Structure-Activity Relationship Studies on Inhibitors of Dihydroorotate Dehydrogenase Based on Pharmacophore Model

Novel Selective and Potent Inhibitors of Malaria Parasite Dihydroorotate Dehydrogenase: Discovery and Optimization of Dihydrothiophenone Derivatives.

Biological Evaluation of Quinoline Derivatives As Inhibitors of Human Dihydroorotate Dehydrogenase

Discovery of Diverse Human Dihydroorotate Dehydrogenase Inhibitors As Immunosuppressive Agents by Structure-Based Virtual Screening.

Design and Synthesis of Isobavachalcone Derivatives As Potential Dihydroorotate Dehydrogenase Inhibitors

Synthesis, Molecular Docking Study, and Cytotoxicity Evaluation of Some Novel 1,3,4-Thiadiazole as Well as 1,3-Thiazole Derivatives Bearing a Pyridine Moiety